Le Lézard
Classified in: Health
Subjects: TDS, TRI, FVT

Launch Version of Equashield's CSTD-Enabled Automated Pharmacy Compounding System to be Showcased at ASHP Midyear Meeting


PORT WASHINGTON, New York, Nov. 27, 2018 /PRNewswire/ -- Equashield (equashield.com), a leading provider of Closed System Transfer Devices (CSTDs) for hazardous drugs, today announced it will demonstrate the launch version of its CSTD-enabled Equashield® Pro Robot at the upcoming ASHP Midyear Meeting.

Equashield Pro is an Automated Pharmacy Compounding System for the safe and efficient preparation of injectable drugs, including hazardous drugs. The system, which utilizes Equashield's flagship CSTD, follows a multi-station compounding method, similar to a manufacturing production line, to minimize time and motion in dosage preparation.

Eight work stations provide a high throughput of up to 60 doses per hour to meet peak-time compounding needs. The Pro's versatility enables it to access all sized drug vials to process a wide range of finished product dosage forms, and its proprietary dose verification system prevents medication errors. Approximately the size of a standard Biological Safety Cabinet, the Equashield Pro facilitates the simple and cost-effective adoption of robotics in hospital pharmacies without the need for costly renovations and maintenance.

"Development of the Equashield Pro focused on three essential criteria: utilizing Equashield's flagship CSTD for extra protection during the hazardous drug compounding process; increasing productivity exponentially; and control of medication errors" said Gonen Daskal, Project Manager and System Architect for the Equashield Pro. "Focusing on these needs ensures that the Equashield Pro is not only ergonomic and innovative, but also provides the safest hazardous drug compounding environment for pharmacists."

The Equashield Pro was selected a Gold Winner in this year's Medical Design Excellence Awards in New York, the medical technology industry's premier design competition. It was also recognized as a "Best of the Best" winner of the Red Dot Award: Product Design 2018 in Germany and cited by the IDEA 2018 International Design Excellence Awards.

Equashield® Pro will be on display at the ASHP Midyear Meeting in Anaheim, CA, December 2-6 at Booth 1223. Visitors may also receive a copy of the ASHP-developed safe handling toolkit at the Equashield booth. Private tours of the Pro, outside of show hours, are available upon request.

About Equashield

Equashield is a leading provider of manual and automated solutions for the compounding and administration of hazardous drugs. Equashield's product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD® Pro, the first ever closed system-enabled Automated Pharmacy Compounding System. Equashield's CSTD is clinically-proven to protect healthcare professionals from hazardous drug exposure. EQUASHIELD II covers more routes of exposure than alternative systems and has passed the proposed 2015 alcohol vapor containment protocol from NIOSH, confirming that it can contain the harshest vapors & emissions. Studies have shown Equashield's CSTD as faster to deploy and easier to use than competing systems. Used by hundreds of hospitals and clinics around the world, EQUASHIELD II is CE marked and substantiated by the FDA for preventing microbial ingress for up to seven days.

Follow Equashield on LinkedInTwitter and Facebook.

For more information: http://www.equashield.com

Media Contact:
Finn Partners for Equashield
Nicole Grubner
[email protected]
@nicolegrubner
+1-929-222-8011

 

 

SOURCE Equashield


These press releases may also interest you

at 12:46
Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today a milestone for its iTindtm device with its availability and greater patient access through the largest healthcare group...

at 12:46
Amid the demands of dentistry, where resilience is paramount, practitioners confront challenges beyond clinical skills alone. Thriving in this environment requires a particular mindset, enabling professionals to adeptly navigate pressures, maintain...

at 12:45
The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering. The global smart insulin pens market accounted for USD 0.769 billion in 2023 and is expected to reach at USD 2.30 billion by 2034 with a CAGR of...

at 12:35
MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating CNS...

at 12:27
This year marks the 14th anniversary of the enactment of the Affordable Care Act (ACA). Its passage was the most significant advancement of health policy since the establishment of Medicare and Medicaid in the 1960s and made healthcare accessible and...

at 12:15
ResBiotic Nutrition, Inc. (ResBiotic), the pioneering physician-developed pre/probiotic wellness scale-up, proudly announces the appointments of Stefany Nieto as Vice President of Operations and Brittany Zenner as Director of Marketing. Nieto is a...



News published on and distributed by: